Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Value-Added Medicines

Set Alert for Value-Added Medicines

Rani Therapeutics: ‘We’ve Tested A Dozen Molecules, All Of Them Have Worked’

In an exclusive interview with Generics Bulletin, Talat Imran, CEO of oral-dose biologics player Rani Therapeutics, talks adalimumab, partnering opportunities and financing, in the wake of kicking off pre-clinical development of its RT-111 proposed biosimilar to Janssen’s Stelara (ustekinumab) contained in its proprietary RaniPill Go ‘robotic’ capsule.

Biosimilars Value-Added Medicines

Hyloris Ramps Up Product Expansion With New Idiopathic Rhinitis Spray

Hyloris Pharmaceuticals’ new idiopathic rhinitis treatment sets it on track to achieve its target of around 30 portfolio assets by the end of 2024. 

Value-Added Medicines Strategy

What’s Next? Five Things To Look Out For In December

In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.

Biosimilars Generic Drugs

Teva To Advance Digihaler Data Ecosystem With Rimdi And HealthSnap

Teva’s new partnerships will make patient data from its digital inhalers more accessible to healthcare providers, potentially placing Teva’s asthma platform at the forefront of emerging treatment paradigms.

Value-Added Medicines Deals

Advanz Zeroes In On Innovative Assets And M&A

Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.

Value-Added Medicines M & A

Five Things Facing Teva’s New CEO Richard Francis

With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.

Biosimilars Generic Drugs

Teva Targets Risperidone LAI In H1 2023 Following Earlier FDA Snub

Teva maintains that the clinical data package looks sounds for it and partner MedinCell’s proposed 505(b)(2) hybrid risperidone long-acting injectable product, as the firms look to muscle in on the multi-billion-dollar LAI schizophrenia market next year.

Value-Added Medicines Strategy

Accord And Sandoz Lead Victories At GGB Awards 2022

Accord and Sandoz were the big winners at the Global Generics & Biosimilars Awards 2022 in Frankfurt, with other firms recognized including Beximco, Centrient, Dr Reddy’s, Eurofarma, Samsung Bioepis, Shanghai Henlius Biotech and Stada, as well as the US Biosimilars Forum.

Generic Drugs Biosimilars

Rani Therapeutics Gets Ball Rolling On Oral Stelara Biosimilar

California-based Rani Therapeutics has provided several key pipeline updates and targets, ahead of plans to accelerate development of its proprietary RaniPill Go ‘robotic’ capsule technology in 2023.

Biosimilars Value-Added Medicines
See All
UsernamePublicRestriction

Register